In silico analysis for antiviral therapies against SARS-CoV-2
December 2020
University of Tübingen, Tübingen, Germany
The authors used a computational approach to discover new metabolic antiviral targets against SARS-CoV-2. An integrated host-virus genome-scale metabolic model of human alveolar macrophages and SARS-CoV-2 identified the enzyme guanylate kinase as one potential target, showing that its knock-out prevents virus growth, while not affecting the host. Since guanylate kinase inhibitors are described in the literature, the authors propose the assessment of their potential therapeutic effects for SARS-CoV-2 infections.
FBA reveals guanylate kinase as a potential target for antiviral therapies against SARS-CoV-2
Alina Renz, Andreas Dräger
Added on: 01-06-2021
[1] https://academic.oup.com/bioinformatics/article/36/Supplement_2/i813/6055936[2] https://www.medwiss.de/2021/01/04/sars-cov-2-bioinformatiker-entdecken-eine-neue-schwachstelle-des-virus/?utm_source=DGP_Fachletter_Aerzte-A&utm_medium=E-Mail&utm_campaign=DGP_Fachletter_Aerzte-A
